{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(4)"],"submitter":["Williams LD"],"pubmed_abstract":["<h4>Introduction</h4>SARS-CoV-2, responsible for the coronavirus disease (COVID-19) pandemic, may impact other systems apart from the respiratory system, including the nervous system. In this systematic review, we aimed to establish the prevalence and determinants of neuropathic pain amongst COVID-19-infected individuals.<h4>Methodology</h4>A literature search in the PubMed database was performed and 11 papers were eligible for inclusion in this systematic review and meta-analysis.<h4>Results</h4>The pooled prevalence of COVID-19-related neuropathic pain was 6.7% (95% CI: 4.7-9.5%) for hospitalised patients during the acute phase and 34.3% (95% CI: 14.3-62%) for long COVID patients. The identified risk factors for COVID-19-related neuropathic pain development included depression, COVID-19 severity and azithromycin use.<h4>Conclusions</h4>Neuropathic pain is a very common symptom in long COVID, indicating the urgency for further research in this direction."],"journal":["Journal of clinical medicine"],"pagination":["1672"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9966617"],"repository":["biostudies-literature"],"pubmed_title":["COVID-19-Related Neuropathic Pain: A Systematic Review and Meta-Analysis."],"pmcid":["PMC9966617"],"pubmed_authors":["Zis P","Williams LD"],"additional_accession":[]},"is_claimable":false,"name":"COVID-19-Related Neuropathic Pain: A Systematic Review and Meta-Analysis.","description":"<h4>Introduction</h4>SARS-CoV-2, responsible for the coronavirus disease (COVID-19) pandemic, may impact other systems apart from the respiratory system, including the nervous system. In this systematic review, we aimed to establish the prevalence and determinants of neuropathic pain amongst COVID-19-infected individuals.<h4>Methodology</h4>A literature search in the PubMed database was performed and 11 papers were eligible for inclusion in this systematic review and meta-analysis.<h4>Results</h4>The pooled prevalence of COVID-19-related neuropathic pain was 6.7% (95% CI: 4.7-9.5%) for hospitalised patients during the acute phase and 34.3% (95% CI: 14.3-62%) for long COVID patients. The identified risk factors for COVID-19-related neuropathic pain development included depression, COVID-19 severity and azithromycin use.<h4>Conclusions</h4>Neuropathic pain is a very common symptom in long COVID, indicating the urgency for further research in this direction.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T00:05:12.643Z","creation":"2025-02-18T23:58:04.963Z"},"accession":"S-EPMC9966617","cross_references":{"pubmed":["36836207"],"doi":["10.3390/jcm12041672"]}}